Yisheng Biotechnology Co., Ltd. (“Yisheng Biotech Group and Company”) was incorporated in the Cayman Islands on July 31, 2000, and listed on the Hong Kong Stock Exchange on June 27, 2001. The Group's main business is the manufacture and sale of biopharmaceuticals for the treatment of body surface trauma and eye damage. In addition, it is also engaged in the development of bFGF drugs and other eye medicine projects for new indications. The group has now successfully developed a series of genetically engineered biopharmaceuticals. Three of these products have been classified as national-level Class I new drugs. The main brands are Beifuji, Beifuxu, and Beifuxin.
No Data
No Data